Mostrar el registro sencillo del ítem

dc.contributor.authorVera, Ruth
dc.contributor.authorGómez, María Luisa
dc.contributor.authorAyuso, Juan Ramón
dc.contributor.authorFigueras, Joan
dc.contributor.authorGarcía-Alfonso, Pilar
dc.contributor.authorMartínez, Virginia
dc.contributor.authorLacasta, Adelaida
dc.contributor.authorRuiz-Casado, Ana
dc.contributor.authorSafont, María José
dc.contributor.authorAparicio, Jorge
dc.contributor.authorCampos, Juan Manuel
dc.contributor.authorCámara, Juan Carlos
dc.contributor.authorMartín-Richard, Marta
dc.contributor.authorMontagut, Clara
dc.contributor.authorPericay, Carles
dc.contributor.authorVieitez, Jose María
dc.contributor.authorFalcó, Esther
dc.contributor.authorJorge Fernández, Monica 
dc.contributor.authorMarín, Miguel
dc.contributor.authorSalgado Fernández, Mercedes 
dc.contributor.authorViúdez, Antonio
dc.date.accessioned2022-03-23T08:56:10Z
dc.date.available2022-03-23T08:56:10Z
dc.date.issued2020
dc.identifier.issn2072-6694
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32806731es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16387
dc.description.abstractBackground: The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. Methods: Eligible patients were aged >/=18 years, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and histologically-confirmed colon or rectal adenocarcinoma with measurable liver metastases. Preoperative treatment was bevacizumab (7.5 mg on day 1) + XELOX (oxaliplatin 130 mg/m(2), capecitabine 1000 mg/m(2) bid on days 1-14 q3w). After three cycles, response was evaluated by a multidisciplinary team. Patients who were progression-free and metastasectomy candidates received one cycle of XELOX before undergoing surgery 3-5 weeks later, followed by four cycles of bevacizumab + XELOX. Results: A total of 83 patients entered the study; 68 were eligible for RECIST, 67 for CTMC, and 51 for pathological response evaluation. Of these patients, 49% had a complete or partial RECIST response, 91% had an optimal or incomplete CTMC response, and 81% had a complete or major pathological response. CTMC response predicted 37 of 41 pathological responses versus 23 of 41 responses predicted using RECIST (p = 0.008). Kappa coefficients indicated a lack of correlation between the results of RECIST and morphological responses and between morphological and pathological response rates. Conclusion: CTMC may represent a better marker of pathological response to bevacizumab + XELOX than RECIST in patients with potentially-resectable CRC liver metastases.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleCorrelation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.en
dc.typeJournal Articlees
dc.authorsophosVera, Ruth;Gómez, María Luisa;Ayuso, Juan Ramón;Figueras, Joan;García-Alfonso, Pilar;Martínez, Virginia;Lacasta, Adelaida;Ruiz-Casado, Ana;Safont, María José;Aparicio, Jorge;Campos, Juan Manuel;Cámara, Juan Carlos;Martín-Richard, Marta;Montagut, Clara;Pericay, Carles;Vieitez, Jose María;Falcó, Esther;Jorge, Mónica;Marín, Miguel;Salgado, Mercedes;Viúdez, Antonio
dc.identifier.doi10.3390/cancers12082259
dc.identifier.pmid32806731
dc.identifier.sophos36908
dc.issue.number8es
dc.journal.titleCancers (Basel)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUOes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number12es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional